RedHill Replaces its Co-Commercialization Agreement with Daiichi Sankyo for Movantik (naloxegol)

 RedHill Replaces its Co-Commercialization Agreement with Daiichi Sankyo for Movantik (naloxegol)

RedHill Biopharma Reports the Submission of CTA for P-II/III Study Evaluating Opaganib Against COVID-19 in Russia

Shots:

  • The new agreement involves, Daiichi to get royalties on sales of Movantik plus payments each year starting from 2021 to 2023. RedHill to take care of all the responsibilities and costs to commercialize Movantik in the US. Additionally, under a subscription agreement Daiichi will get 283,387 shares in RedHill Biopharma as partial consideration in relation to Movantik
  • In Apr 2020, AstraZeneca granted exclusive WW rights (ex- EU, Canada, Israel) to RedHill for the treatment of opioid-induced constipation while promoting the product in the US
  • Movantik (naloxegol) is qd oral PAMORA approved to treat patients with OIC in adults also recommended by the American Gastroenterological Association (AGA) guidelines and the National Comprehensive Cancer Network (NCCN) guidelines. In 2019, Movantik generated sales of $96M

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Behnace

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post